Menu Search
Equities

Voyageur Pharmaceuticals Ltd

VYYRF:PKC

Voyageur Pharmaceuticals Ltd

Actions
  • Price (USD)0.045
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-7.41%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada and the state of Utah, United States. Its properties include Jubilee Mountain, Falcon and Paradox Basin. It owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. It holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, United States. It owns a 100% interest in two battery mineral projects that is focused on copper/zinc development. Its pipeline products include SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101 and VY-103.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-1.35m
  • Incorporated2008
  • Employees--
  • Location
    Voyageur Pharmaceuticals LtdDome Tower 800, 333 7 Ave. S.W.CALGARY T2P 2Z1CanadaCAN
  • Phone+1 (403) 923-5944
  • Fax+1 (403) 508-2670
  • Websitehttps://voyageurpharmaceuticals.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.